Literature DB >> 14503961

Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.

Iris Verel1, Gerard W M Visser, Otto C Boerman, Julliette E M van Eerd, Ron Finn, Ronald Boellaard, Maria J W D Vosjan, Marijke Stigter-van Walsum, Gordon B Snow, Guus A M S van Dongen.   

Abstract

Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT) candidates to confirm tumor targeting and to estimate radiation doses to tumor and normal tissues. One of the requirements to be set for such a scouting procedure is that the biodistributions of the diagnostic and therapeutic radioimmunoconjugates should be similar. In the present study we evaluated the potential of the positron emitters zirconium-89 ((89)Zr) and iodine-124 ((124)I) for this approach, as these radionuclides have a relatively long half-life that matches with the kinetics of MAbs in vivo (t(1/2) 3.27 and 4.18 days, respectively). After radiolabeling of the head and neck squamous cell carcinoma (HNSCC)-selective chimeric antibody (cMAb) U36, the biodistribution of two diagnostic (cMAb U36-N-sucDf-(89)Zr and cMAb U36-(124)I) and three therapeutic radioimmunoconjugates (cMAb U36-p-SCN-Bz-DOTA-(88)Y-with (88)Y being substitute for (90)Y, cMAb U36-(131)I, and cMAb U36-MAG3-(186)Re) was assessed in mice with HNSCC-xenografts, at 24, 48, and 72 hours after injection. Two patterns of biodistribution were observed, one pattern matching for (89)Zr- and (88)Y-labeled cMAb U36 and one pattern matching for (124)I-, (131)I-, and (186)Re-cMAb U36. The most remarkable differences between both patterns were observed for uptake in tumor and liver. Tumor uptake levels were 23.2 +/- 0.5 and 24.1 +/- 0.7%ID/g for the (89)Zr- and (88)Y-cMAb U36 and 16.0 +/- 0.8, 15.7 +/- 0.79 and 17.1 +/- 1.6%ID/g for (124)I-, (131)I-, and (186)Re-cMAb U36-conjugates, respectively, at 72 hours after injection. For liver these values were 6.9 +/- 0.8 ((89)Zr), 6.2 +/- 0.8 ((88)Y), 1.7 +/- 0.1 ((124)I), 1.6 +/- 0.1 ((131)I), and 2.3 +/- 0.1 ((186)Re), respectively. These preliminary data justify the further development of antibody-PET with (89)Zr-labeled MAbs for scouting of therapeutic doses of (90)Y-labeled MAbs. In such approach (124)I-labeled MAbs are most suitable for scouting of (131)I- and (186)Re-labeled MAbs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503961     DOI: 10.1089/108497803322287745

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  40 in total

Review 1.  PET tracers based on Zirconium-89.

Authors:  Yin Zhang; Hao Hong; Weibo Cai
Journal:  Curr Radiopharm       Date:  2011-04

2.  Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.

Authors:  Arutselvan Natarajan; Frezghi Habte; Sanjiv S Gambhir
Journal:  Bioconjug Chem       Date:  2012-06-11       Impact factor: 4.774

3.  Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.

Authors:  Nerissa Therese Viola-Villegas; Samuel L Rice; Sean Carlin; Xiaohong Wu; Michael J Evans; Kuntal K Sevak; Marija Drobjnak; Govind Ragupathi; Ritsuko Sawada; Wolfgang W Scholz; Philip O Livingston; Jason S Lewis
Journal:  J Nucl Med       Date:  2013-09-12       Impact factor: 10.057

4.  Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

Authors:  Marc-André Fortin; Alexei V Salnikov; Marika Nestor; Nils-Erik Heldin; Kristofer Rubin; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-03       Impact factor: 9.236

Review 5.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

Review 6.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

7.  The pharmacokinetics of Zr-89 labeled liposomes over extended periods in a murine tumor model.

Authors:  Jai Woong Seo; Lisa M Mahakian; Sarah Tam; Shengping Qin; Elizabeth S Ingham; Claude F Meares; Katherine W Ferrara
Journal:  Nucl Med Biol       Date:  2014-09-28       Impact factor: 2.408

Review 8.  Is there still a role for SPECT-CT in oncology in the PET-CT era?

Authors:  Rodney J Hicks; Michael S Hofman
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

9.  Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.

Authors:  Jason P Holland; Eloisi Caldas-Lopes; Vadim Divilov; Valerie A Longo; Tony Taldone; Danuta Zatorska; Gabriela Chiosis; Jason S Lewis
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

10.  p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.

Authors:  Lars R Perk; Maria J W D Vosjan; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.